Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 4, Issue 1
  5. Article
Volume 4, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children. The consequences of ADHD could seriously impact the patient’s life, and thus parental training, behavioral therapies, and pharmacological interventions are the main therapeutic options applied. This study was conducted to explore the trends of prescribing pharmacological medications used in ADHD and identify the reasons for discontinuation of such medications.

Methodology

A retrospective chart review for patients diagnosed with ADHD at Child and Adolescent Mental Health Services (CAMHS) in Qatar from January 2019 to December 2019 was carried out. Patients less than 18 years old, diagnosed with ADHD as per the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and were on pharmacological treatment for ADHD were suitable to be included. Patients who were not on anti-ADHD medications were excluded from the study.

Results

Ninety-two patients were eligible to be included in the study. Autism Spectrum Disorder (ASD) was found to be the most coexisting condition in addition to ADHD in 16.3%. Methylphenidate was the most prescribed medication (68.5%), followed by atomoxetine (30.4%). None of the participants were found on modafinil, guanfacine, bupropion, or benzodiazepines, and none exceeded the maximum licensed dose of either methylphenidate or atomoxetine. Half (50%) of the sample on atomoxetine discontinued treatment compared to 14.2% in the methylphenidate group.

Conclusion

The clinical practice of prescribing pharmacological options for ADHD was thoroughly in alignment with international guidelines. The effects of long-term use of these psychotropics in this particular group of patients on their neurobiological, behavioral, and physical health should be studied further.

© 2023 Bentham Science Publishers
© 2023 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/nemj/10.2174/04666221229092808
2023-02-16
2025-01-19

  • From This Site

    /content/journals/nemj/10.2174/04666221229092808
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/4/1/NEMJ-4-1-E291222212261.html?itemId=/content/journals/nemj/10.2174/04666221229092808&mimeType=html&fmt=ahah

References

  1. Beau-LejdstromR DouglasI EvansSJ SmeethL Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence.BMJ Open201666e01050810.1136/bmjopen‑2015‑010508
     [Google Scholar]
  2. PolanczykG.V. SalumG.A. SugayaL.S. CayeA. RohdeL.A. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents.J. Child Psychol. Psychiatry201556334536510.1111/jcpp.1238125649325
     [Google Scholar]
  3. BenerA. QahtaniR.A. AbdelaalI. The prevalence of ADHD among primary school children in an Arabian society.J. Atten. Disord.2006101778210.1177/108705470528450016840595
     [Google Scholar]
  4. BradshawL.G. KamalM. Prevalence of ADHD in Qatari school-age children.J. Atten. Disord.201721544244910.1177/108705471351754524412969
     [Google Scholar]
  5. MannuzzaS. KleinR.G. Long-term prognosis in attention-deficit/hyperactivity disorder.Child Adolesc. Psychiatr. Clin. N. Am.20009371172610.1016/S1056‑4993(18)30114‑710944664
     [Google Scholar]
  6. ThaparA. CooperM. JefferiesR. StergiakouliE. What causes attention deficit hyperactivity disorder?Arch. Dis. Child.201297326026510.1136/archdischild‑2011‑30048221903599
     [Google Scholar]
  7. National Instiutue for health and care excellence. Attention deficit hyperactivity disorder: diagnosis and management [NICE Guideline No. NG87]2019https://www.nice.org.uk/guidance/ng87/resources
  8. GrimmsmannT. HimmelW. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.Eur. J. Clin. Pharmacol.202177110711510.1007/s00228‑020‑02948‑332803292
     [Google Scholar]
  9. AntshelK.M. Zhang-JamesY. FaraoneS.V. The comorbidity of ADHD and autism spectrum disorder.Expert Rev. Neurother.201313101117112810.1586/14737175.2013.84041724117274
     [Google Scholar]
  10. GiacobiniM. MedinE. AhnemarkE. RussoL.J. CarlqvistP. Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden.J. Atten. Disord.201822131310.1177/108705471455461725376193
     [Google Scholar]
  11. MickE. McManusD.D. GoldbergR.J. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.Eur. Neuropsychopharmacol.201323653454110.1016/j.euroneuro.2012.06.01122796229
     [Google Scholar]
  12. WangY. ZhengY. DuY. SongD.H. ShinY.J. ChoS.C. KimB.N. AhnD.H. Marquez-CaraveoM.E. GaoH. WilliamsD.W. LevineL.R. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial.Aust. N. Z. J. Psychiatry200741322223010.1080/0004867060105776717464703
     [Google Scholar]
  13. GajriaK LuM SikiricaV Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - A systematic literature review.Neuropsychiatr Dis Treat20141015436910.2147/NDT.S6572125187718
     [Google Scholar]
  14. BrownJ.T. BishopJ.R. SangkuhlK. NurmiE.L. MuellerD.J. DinhJ.C. GaedigkA. KleinT.E. CaudleK.E. McCrackenJ.T. LeonJ. LeederJ.S. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 ( CYP ) 2D6 genotype and atomoxetine therapy.Clin. Pharmacol. Ther.201910619410210.1002/cpt.140930801677
     [Google Scholar]
/content/journals/nemj/10.2174/04666221229092808
Loading
Pharmacological Treatment of Children and Adolescents Diagnosed with Attention-deficit/hyperactivity Disorder at Mental Health Services in Qatar: A Retrospective Study
NEW Emirates Medical J 4, e291222212261 (2023); https://doi.org/10.2174/04666221229092808
/content/journals/nemj/10.2174/04666221229092808
/content/journals/nemj/10.2174/04666221229092808
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): ADHD; Adolescents; Atomoxetine; Methylphenidate; Neurodevelopment disorder; Prescribing patterns

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test